Pfizer Inc
NYSE: PFE
▲
42.60
+0.20
+0.47%
1 Day
-
Open
42.24
-
Previous Close
42.40
-
Volume (Avg)
23.18M (21.53M)
-
Day's Range
42.19-42.86
-
52Wk Range
34.32-46.47
-
Market Cap.
246.25B
-
Dividend Rate (Yield)
1.44 (3.40%)
-
Beta
0.77
-
Shares Outstanding
5.78B
-
P/E Ratio (EPS)
22.78 (3.95)
Top Stories
-
Pfizer-Lilly drug shown to help reduce back pain in late-stage trial
Reuters 12 hrs ago(Reuters) - A non-opioid painkiller developed by Pfizer Inc and Eli Lilly and Co succeeded in reducing chronic low back pain when used in a stronger dose, results from a late-stage study showed on Tuesday. But a lower dose of the drug, tanezumab, failed to ...
-
Pfizer Receives European Approval for ZIRABEV™ (bevacizumab), a Biosimilar to Avastin®*
MarketWatch -
Merck's Keytruda tops Pfizer's Sutent in first-line kidney cancer
Seeking Alpha -
Lilly and Pfizer's tanezumab successful in late-stage back pain study
Seeking Alpha -
Pfizer's Forgotten Cancer Pill Is About to Become Its Next Blockbuster
The Motley Fool 17 hrs ago -
Higher dose of Pfizer-Lilly drug helps reduce back pain in study
Reuters -
Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain
MarketWatch -
Brokerages Set Pfizer Inc. (PFE) Target Price at $44.88
themarketsdaily.com -
Ochsner, Pfizer to test digital tools to ease patient participation in clinical trials
Becker's Hospital Review -
Ochsner Health and Pfizer to Develop Innovative Models for Clinical Trials
HIT Consultant -
Ochsner Health System and Pfizer form multi-year alliance
WAFB -
Gliknik receives $15M payment from Pfizer after reaching clinical milestone
Technical -
Pfizer, Lilly roll out more late-stage results for non-opioid pain drug
BioPharma Dive -
Ochsner to digitize clinical trials after partnering with pharmaceutical giant Pfizer
The Advocate -
Pfizer and Lilly’s NGF painkiller moves forward, meeting phase 3 endpoints in lower back pain
FierceBiotech 14 hrs ago -
Between Merck and Pfizer, the race is on in kidney cancer—but analysts are calling it early
FiercePharma -
Pneumococcal Vaccines Market Size to Grow By 2028 with Top Players | Pfizer Inc., Sanofi S.A., GlaxoSmithKline Plc..
openpr.com -
Cantor Fitzgerald Sticks to Their Buy Rating for Pfizer (PFE)
smarteranalyst.com
